No Data
Summary of the 2024 Annual Report of Hubei Jichuan Pharmaceutical Co., Ltd.
Hubei Jichuan Pharmaceutical Co., Ltd. 2024 Annual Report
Hubei Jichuan Pharmaceutical Co., Ltd. Report for the first quarter of 2025
Are Investors Undervaluing Hubei Jumpcan Pharmaceutical Co., Ltd. (SHSE:600566) By 49%?
Hubei Jumpcan Pharmaceutical (600566.SH): has repurchased a total of 0.22 million shares.
Gelonghui April 1丨Hubei Jumpcan Pharmaceutical (600566.SH) announced that as of March 31, 2025, the company has cumulatively repurchased 220,500 shares through centralized bidding Trade, accounting for 0.02% of the company's total share capital, with the highest purchase price at 29.00 yuan/share, the lowest price at 27.10 yuan/share, and the total amount paid being 6,099,831 yuan (excluding transaction costs).
Hubei Jumpcan Pharmaceutical's (SHSE:600566) 11% CAGR Outpaced the Company's Earnings Growth Over the Same Five-year Period
Hubei Jumpcan Pharmaceutical Co., Ltd.'s (SHSE:600566) Share Price Boosted 27% But Its Business Prospects Need A Lift Too
